Stężenie frakcji kostnej fosfatazy zasadowej (BALP) i zewnątrzkomórkowej domeny receptora HER-2 (ECD/HER-2) w surowicy krwi, podczas leczenia dzieci i młodzieży z mięsakiem kościopochodnym
, , , and | Apr 12, 2018
About this article
Published Online: Apr 12, 2018
Page range: 58 - 64
Received: Nov 29, 2017
Accepted: Dec 06, 2017
DOI: https://doi.org/10.34763/devperiodmed.20182201.5864
© 2018 Magdalena Rychłowska-Pruszyńska, Joanna Gajewska, Jadwiga Ambroszkiewicz, Marek Karwacki, Katarzyna Szamotulska, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Serum levels of BALP and ECD/HER-2 in patients with osteosarcoma during treatment in comparison with healthy age matched counterparts.Tabela I. Poziomy BALP i ECD/HER-2 w surowicy krwi pacjentów z OS w trakcie leczenia w porównaniu z grupą kontrolną.
| Patients (n=22) |
Controls (n=22) |
|||
|---|---|---|---|---|
| Biopsy |
Pre-operative chemotherapy |
Post-operative chemotherapy |
||
| BALP (U/L) | 136.9 (85.7-240.6) | 53.8 (40.4-84.8)* | 63.8 (43.2-82.4)** | 94.1 (59.4-120.4)** |
| ECD/HER-2 (ng/ml) | 4.95 (3.53-12.3) | 3.86 (2.79-10.08)* | 3.84 (3.06-20.66)* | 4.06 (3.29-5.20)* |
Serum levels of BALP and ECD/HER-2 in osteosarcoma patients depending on the metastasis status at initial diagnosis.Tabela II. Stężenie BALP i ECD/HER-2 w surowicy krwi pacjentów z OS. Pacjenci zostali podzieleni na grupy w zależności od tego czy stwierdzono przerzuty na etapie dinagozy.
| Patients with localized disease (n=13) |
Patients with metastatic disease (n=9) |
|||||
|---|---|---|---|---|---|---|
| Biopsy |
Pre-operative chemotherapy |
Post-operative chemotherapy |
Biopsy |
Pre-operative chemotherapy |
Post-operative chemotherapy |
|
| BALP (U/L) | 89.1(75.4-138.8) | 43.0** (31.9-58.0) | 50.5** (36.8-80.5) | 257.0** (216.5-325.7) | 101.6* (49.7-142.6) | |
| ECD/HER-2 (ng/ml) | 4.58 (3.40-14.20) | 3.86 (2.86-12.9) | 7.98* (3.31-20.66) | 5.11(3.68-6.90) | 3.80 (2.44-5.76) | 3.62 (2.59-6.88) |
Serum levels of BALP and ECD/HER-2 in osteosarcoma patients with remission or progression of disease after therapy.Tabela III. Poziomy BALP i ECD/HER-2 w surowicy krwi pacjentów z remisją lub progresją choroby po terapii.
| Patients with remission (n=16) |
Patients with progression (n=6) |
|
|---|---|---|
| BALP (U/L) | 43.6 (38.4-74.6) | 147.0 (126.5-263.3)* |
| ECD/HER-2 (ng/ml) | 3.56 (2.61-37.62) | 6.41 (4.51-10.59) |